Retinoid_NN
differentiation_NN
therapy_NN
in_IN
promyelocytic_JJ
leukemia_NN
._.

Acute_JJ
promyelocytic_JJ
leukemia_NN
-LRB-_-LRB-
APL_NN
-RRB-_-RRB-
is_VBZ
a_DT
specific_JJ
type_NN
of_IN
acute_JJ
myeloid_JJ
leukemia_NN
characterized_VBN
by_IN
the_DT
morphology_NN
of_IN
the_DT
blast_NN
cells_NNS
,_,
a_DT
specific_JJ
t_NN
-LRB-_-LRB-
15_CD
;_:
17_CD
-RRB-_-RRB-
translocation_NN
,_,
and_CC
risks_NNS
of_IN
definite_JJ
coagulopathy_NN
._.

Recently_RB
this_DT
leukemia_NN
was_VBD
further_RB
characterized_VBN
by_IN
an_DT
exquisite_JJ
sensitivity_NN
to_TO
all-trans_JJ
retinoic_JJ
acid_NN
's_POS
differentiation_NN
effect_NN
and_CC
the_DT
production_NN
of_IN
a_DT
fusion_NN
gene_NN
altering_VBG
the_DT
gene_NN
of_IN
RARalpha_NN
and_CC
a_DT
novel_JJ
gene_NN
PML_NN
._.

In_FW
vivo_FW
differentiation_NN
therapy_NN
with_IN
retinoids_NNS
in_IN
APL_NN
patients_NNS
follows_VBZ
strict_JJ
guidelines_NNS
related_JJ
both_CC
to_TO
the_DT
APL_NN
cell_NN
and_CC
the_DT
biodisposal_NN
of_IN
all-trans_JJ
retinoic_JJ
acid_NN
._.

